Zosa-L Capsule PR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and facilitating gastric emptying, thereby alleviating symptoms associated with functional dyspepsia, gastroesophageal reflux disease (GERD), and delayed gastric emptying. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective relief from acid-related mucosal damage and promoting ulcer healing. The combination of these two agents in Zosa-L Capsule PR offers a synergistic therapeutic effect by simultaneously addressing impaired gastric motility and excessive acid secretion, making it suitable for patients with overlapping symptoms of dyspepsia and acid reflux. The prolonged-release formulation ensures sustained drug release, optimizing therapeutic efficacy and patient compliance. Zosa-L Capsule PR should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to either component, and caution in patients with severe hepatic or renal impairment. Adverse effects may include mild gastrointestinal disturbances, headache, or dizziness. Regular monitoring is advised during prolonged therapy.